首页> 外文期刊>Archives of disease in childhood >A new mixed micellar preparation for oral vitamin K prophylaxis: randomised controlled comparison with an intramuscular formulation in breast fed infants.
【24h】

A new mixed micellar preparation for oral vitamin K prophylaxis: randomised controlled comparison with an intramuscular formulation in breast fed infants.

机译:口服维生素K预防的新混合胶束制剂:与母乳喂养婴儿肌肉内制剂的随机对照比较。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVE: To compare a new oral preparation of vitamin K1 (Konakion MM) containing lecithin and glycocholic acid with a standard intramuscular (IM) preparation during the first 8 weeks of life in exclusively breast fed infants. METHODS: Infants were randomised at birth to the IM group (1 mg vitamin K) or the oral group (2 mg given at birth and repeated at 7 and 30 days of life). Prothrombin time (INR), plasma vitamin K1, and PIVKA II (undercarboxylated prothrombin) were monitored at 14, 30, and 56 days of age. RESULTS: Seventy nine infants were randomised to the oral group and 77 to the IM group. Sixty seven infants in each group completed eight weeks of the study. Prothrombin times did not differ between the two groups. Mean (SD) plasma vitamin K1 values (in ng/ml) decreased in both groups over time, but were higher in the oral group at 14 and 56 days: 2.0 (1.6) v 1.3 (1.1) at 14 days; 0.5 (0.3) v 0.5 (0.7) at 30 days; and 0.5 (0.8) v 0.2 (0.2) at 56 days of life. PIVKA II was raised (> or = 0.1 AU/ml) in cord blood in 47% of the infants. By 14 days, only one infant in each group had a raised PIVKA II value and both of these initially had high concentrations of PIVKA II in cord blood. At 30 days, there were no raised PIVKA II values. At 56 days, there were no raised PIVKA II values in the oral group, although three infants in the IM group had raised values. CONCLUSIONS: Plasma vitamin K concentrations were at least equal or significantly higher in babies given oral vitamin K supplements compared with IM treated babies at the time points measured. Through the first 8 weeks of life, multiple doses of the new oral preparation maintain haemostasis and vitamin K status in breast fed infants at least equal to that of the intramuscular preparation.
机译:目的:比较纯母乳喂养婴儿在出生后头8周内含有卵磷脂和糖胆酸的新型维生素K1口服制剂(Konakion MM)与标准肌内(IM)制剂的比较。方法:婴儿在出生时被随机分为IM组(1 mg维生素K)或口服组(出生时2 mg,并在7天和30天重复)。分别在14、30和56天龄时监测凝血酶原时间(INR),血浆维生素K1和PIVKA II(羧化凝血酶原不足)。结果:79例婴儿随机分为口服组和77例IM组。每组中有67名婴儿完成了八周的研究。两组之间的凝血酶原时间无差异。两组的平均(SD)血浆维生素K1值(以ng / ml为单位)随时间降低,但口服组在14天和56天时较高:14天时为2.0(1.6)对1.3(1.1); 30天时为0.5(0.3)对0.5(0.7);寿命56天时分别为0.5(0.8)v 0.2(0.2)。 47%的婴儿的脐带血中PIVKA II升高(>或= 0.1 AU / ml)。到14天时,每组中只有一名婴儿的PIVKA II值升高,并且这两个婴儿最初在脐血中的PIVKA II浓度都很高。在30天时,PIVKA II值没有升高。在第56天,口服治疗组的PIVKA II值没有升高,尽管IM组的三名婴儿升高了。结论:口服IMK补充剂的婴儿血浆IMK浓度至少等于或明显高于IM治疗的婴儿。在生命的头8周内,多次口服新制剂可保持母乳喂养婴儿的止血和维生素K状态至少与肌肉注射制剂相同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号